Contineum Therapeutics GAAP EPS of -$0.49
Tickers: $CTNM
Read the full article at Seeking Alpha
Part of the story Seaport Therapeutics Reports Q3 GAAP EPS of -$0.49, Exceeding Analyst Expectations (3 articles)
More World news
- Barclays Upgrades Steel Producers Cleveland-Cliffs and Reliance Amid Market Selloff
- Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan
- Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026
- MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion
- Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA
- Chicago Atlantic BDC Reports Q3 2026 Growth in Net Investment Income and Record Portfolio Value
- Google Integrates Gemini 4 Hydrogen Model into Search to Enhance Complex Query Handling
- General Motors Partners with NorthStar Clean Energy for Large-Scale Solar Project in Michigan
- CNBC Select Names Accredited Debt Relief Best for Debt Resources
- CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth